Nadia Heramvand
Overview
Explore the profile of Nadia Heramvand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duse D, Grone M, Kramser N, Ortkemper M, Quast C, Voss F, et al.
Diagnostics (Basel)
. 2023 Feb;
13(3).
PMID: 36766585
Although a moderate proportion of cardiac arrest (CA) patients achieve a return of spontaneous circulation (ROSC), few survive to discharge, mostly with poor neurological development. As serum phosphate levels were...
2.
Wischmann P, Bruno R, Wernly B, Wolff G, Afzal S, Rezar R, et al.
Eur Heart J Open
. 2022 Aug;
2(4):oeac040.
PMID: 35919579
Aims: Patients with acute coronary syndrome (ACS) frequently suffer from anaemia, but its role in patients admitted to an intensive care unit (ICU) is unclear. This analysis evaluates the prognostic...
3.
Heramvand N, Masyuk M, Muessig J, Nia A, Karathanos A, Polzin A, et al.
J Thromb Thrombolysis
. 2022 Apr;
54(2):301-308.
PMID: 35482154
Tirofiban is a glycoproteine (GP) IIb/IIIa receptor antagonist, which inhibits platelet-platelet aggregation and is a potential adjunctive antithrombotic treatment in patients with acute coronary syndromes (ACS) or high-risk percutaneous coronary...
4.
Wernly B, Heramvand N, Mirna M, Kelm M, Lichtenauer M, Dudzinski D, et al.
J Intensive Care Med
. 2020 Jul;
35(10):1141-1142.
PMID: 32602394
No abstract available.
5.
Wernly B, Heramvand N, Masyuk M, Rezar R, Bruno R, Kelm M, et al.
Eur J Intern Med
. 2020 Mar;
76:76-81.
PMID: 32143899
Rationale And Objectives: Acidosis and hyperlactatemia predict outcome in critically ill patients. We assessed BE and pH for risk prediction capabilities in a sub-group of septic patients in the MIMIC-III...
6.
Masyuk M, Heramvand N, Muessig J, Nia A, Polzin A, Kollmann M, et al.
Clin Hemorheol Microcirc
. 2017 Oct;
68(4):421-425.
PMID: 29036802
Background: Cangrelor is an intravenous adenosine diphosphate (ADP) P2Y12 receptor antagonist, which has to be administered as a bolus followed by immediate infusion. Nevertheless, in clinical routine deviations from the...